Efeito dos inibidores do co-transportador sódio-glicose tipo 2 sobre o desfecho renal: Uma revisão integrativa
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/40810 |
Resumo: | Chronic kidney disease (CKD) is characterized by progressive kidney damage with a drop in glomerular filtration rate for a period longer than three months. Among the main causes of CKD in the Brazilian population are type 2 diabetes mellitus (DM2) and systemic arterial hypertension (SAH). Drug therapy with Sodium-glucose cotransporter type 2 inhibitors (iSGLT-2) allows control of the loss of renal function and decreases the need for patients to need renal replacement therapy such as hem dialysis. Objective: To understand the effects of iSGLT-2 in reducing renal outcome, in order to know its benefits and adverse events. Methodology: This is an integrative literature review from the january 2017 to january the 2022, in the electronic databases SCIELO, PUBMED and LILACS, including work in Portuguese and English. The flow diagram was used as a tool for organizing and analyzing the articles. The works of interest were analyzed and then the results with their respective bibliographic data were organized in a frame. Results: Twelve randomized clinical trials were analyzed, of which 5 (42%) studies on canagliflozin, 4 (33%) studies on dapagliflozin, 2 (17%) on empagliflozin and only 1 (8%) study on ertugliflozin. Conclusion: SGLT-2 inhibitors are a new class of drugs that have been shown in several studies to reduce unfavorable renal outcomes, with few side effects, proving to be an important therapeutic tool in the treatment of the population of patients with renal disease. |
id |
UNIFEI_8c82767ee3f07147efd409aa26d04f74 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/40810 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Efeito dos inibidores do co-transportador sódio-glicose tipo 2 sobre o desfecho renal: Uma revisão integrativaEffect of sodium-glucose cotransporter type 2 inhibitors on renal outcome: An integrative reviewEfecto de los inhibidores del cotransportador de sódio-glucosa tipo 2 sobre el resultado renal: Una revisión integradora Inibidores do transportador 2 de sódio-glicoseFalência renal crônicaDiabetes mellitus tipo 2.Inhibidores del transportador de sodio-glucosa 2insuficiencia renal crónicaDiabetes mellitus tipo 2. Sodium-glucose transporter 2 inhibitorsChronic kidney failureType 2 diabetes mellitus.Chronic kidney disease (CKD) is characterized by progressive kidney damage with a drop in glomerular filtration rate for a period longer than three months. Among the main causes of CKD in the Brazilian population are type 2 diabetes mellitus (DM2) and systemic arterial hypertension (SAH). Drug therapy with Sodium-glucose cotransporter type 2 inhibitors (iSGLT-2) allows control of the loss of renal function and decreases the need for patients to need renal replacement therapy such as hem dialysis. Objective: To understand the effects of iSGLT-2 in reducing renal outcome, in order to know its benefits and adverse events. Methodology: This is an integrative literature review from the january 2017 to january the 2022, in the electronic databases SCIELO, PUBMED and LILACS, including work in Portuguese and English. The flow diagram was used as a tool for organizing and analyzing the articles. The works of interest were analyzed and then the results with their respective bibliographic data were organized in a frame. Results: Twelve randomized clinical trials were analyzed, of which 5 (42%) studies on canagliflozin, 4 (33%) studies on dapagliflozin, 2 (17%) on empagliflozin and only 1 (8%) study on ertugliflozin. Conclusion: SGLT-2 inhibitors are a new class of drugs that have been shown in several studies to reduce unfavorable renal outcomes, with few side effects, proving to be an important therapeutic tool in the treatment of the population of patients with renal disease.La enfermedad renal crónica (ERC) se caracteriza por un daño renal progresivo con una caída en la tasa de filtración glomerular por un período mayor a tres meses. Las principales causas de ERC en la población brasileña son la diabetes mellitus tipo 2 (DM2) y la hipertensión arterial sistémica (HAS). La terapia farmacológica con inhibidores del cotransportador de sodio-glucosa tipo 2 (iSGLT-2) permite el control de la pérdida de la función renal y disminuye la necesidad de que los pacientes necesiten terapia de reemplazo renal como la hemodiálisis. Objetivo: Comprender los efectos de iSGLT-2 en la reducción del resultado renal, para conocer sus beneficios y eventos adversos. Metodología: Se trata de una revisión integrativa de la literatura de enero de 2017 a enero de 2022, en las bases de datos electrónicas SCIELO, PUBMED y LILACS, incluyendo trabajos en português y inglês. El diagrama de flujo se utilizó como herramienta para organizar y analizar los artículos. Se analizaron los trabajos de interés y luego se organizaron en una tabla los resultados con sus respectivos datos bibliográficos. Resultados: Se analizaron doce ensayos clínicos aleatorizados, de los cuales 5 (42%) fueron estudios sobre canagliflozina, 4 (33 % estudios sobre dapagliflozina, 2 (17%) sobre empagliflozina y solo 1 (8%) estudio sobre ertugliflozina. Conclusión: Los inhibidores de SGLT2 son una nueva clase de fármacos que han demostrado en varios estudios reducir los resultados renales desfavorables, con pocos efectos secundarios, demostrando ser una importante herramienta terapéutica en el tratamiento de la población de pacientes con enfermedad renal.A doença renal crônica (DRC) caracteriza-se por lesão renal de forma progressiva com queda na taxa de filtração glomerular por um período maior que três meses. As principais causas de DRC na população brasileira são o diabetes mellitus tipo 2 (DM2) e a hipertensão arterial sistêmica (HAS). A terapia medicamentosa com inibidores do co-transportador sódio-glicose tipo 2 (iSGLT-2), permite controle da perda da função renal e diminuição da necessidade de pacientes precisarem de terapia renal substitutiva como hemodiálise. Objetivo: Compreender os efeitos dos iSGLT-2 na redução do desfecho renal, a fim de conhecer seus benefícios e eventos adversos. Metodologia: Trata-se de uma revisão integrativa da literatura entre os períodos de janeiro de 2017 a janeiro de 2022, nas bases de dados eletrônicas SCIELO, PUBMED e LILACS, incluindo trabalho em língua portuguesa e inglesa. O diagrama de flow foi utilizado como ferramenta de organização e análise dos artigos. Os trabalhos de interesse foram analisados e, em seguida, os resultados com seus respectivos dados bibliográficos foram organizados em um quadro. Resultados: Foram analisados 12 ensaios clínicos randomizados, dos quais 5 (42%) estudos sobre canagliflozina, 4 (33%) estudos sobre a dapagliflozina, 2 (17%) sobre a empagliflozina e apenas 1 (8%) estudo com a ertugliflozina. Conclusão: Os inibidores de SGLT2 são uma nova classe de medicamentos que demonstrou nos diversos estudos, redução de desfechos renais desfavoráveis, com poucos efeitos colaterais, se mostrando uma ferramenta terapêutica importante no tratamento da população de pacientes com doença renal.Research, Society and Development2023-03-20info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/4081010.33448/rsd-v12i3.40810Research, Society and Development; Vol. 12 No. 3; e29512340810Research, Society and Development; Vol. 12 Núm. 3; e29512340810Research, Society and Development; v. 12 n. 3; e295123408102525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/40810/33295Copyright (c) 2023 Cristiene Neta de Sá Araújo; Letícia Macêdo de Oliveira; Yasmim Campos Rodrigues; Luciane de Jesus Mendes Santos; Rafaella Lopes Ferreira; Willyanna Ravanielly Oliveira de Carvalho; Even Kaline Varella Jardimhttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessAraújo, Cristiene Neta de Sá Oliveira, Letícia Macêdo de Rodrigues, Yasmim Campos Santos, Luciane de Jesus Mendes Ferreira, Rafaella Lopes Carvalho, Willyanna Ravanielly Oliveira de Jardim, Even Kaline Varella 2023-03-23T08:33:38Zoai:ojs.pkp.sfu.ca:article/40810Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2023-03-23T08:33:38Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Efeito dos inibidores do co-transportador sódio-glicose tipo 2 sobre o desfecho renal: Uma revisão integrativa Effect of sodium-glucose cotransporter type 2 inhibitors on renal outcome: An integrative review Efecto de los inhibidores del cotransportador de sódio-glucosa tipo 2 sobre el resultado renal: Una revisión integradora |
title |
Efeito dos inibidores do co-transportador sódio-glicose tipo 2 sobre o desfecho renal: Uma revisão integrativa |
spellingShingle |
Efeito dos inibidores do co-transportador sódio-glicose tipo 2 sobre o desfecho renal: Uma revisão integrativa Araújo, Cristiene Neta de Sá Inibidores do transportador 2 de sódio-glicose Falência renal crônica Diabetes mellitus tipo 2. Inhibidores del transportador de sodio-glucosa 2 insuficiencia renal crónica Diabetes mellitus tipo 2. Sodium-glucose transporter 2 inhibitors Chronic kidney failure Type 2 diabetes mellitus. |
title_short |
Efeito dos inibidores do co-transportador sódio-glicose tipo 2 sobre o desfecho renal: Uma revisão integrativa |
title_full |
Efeito dos inibidores do co-transportador sódio-glicose tipo 2 sobre o desfecho renal: Uma revisão integrativa |
title_fullStr |
Efeito dos inibidores do co-transportador sódio-glicose tipo 2 sobre o desfecho renal: Uma revisão integrativa |
title_full_unstemmed |
Efeito dos inibidores do co-transportador sódio-glicose tipo 2 sobre o desfecho renal: Uma revisão integrativa |
title_sort |
Efeito dos inibidores do co-transportador sódio-glicose tipo 2 sobre o desfecho renal: Uma revisão integrativa |
author |
Araújo, Cristiene Neta de Sá |
author_facet |
Araújo, Cristiene Neta de Sá Oliveira, Letícia Macêdo de Rodrigues, Yasmim Campos Santos, Luciane de Jesus Mendes Ferreira, Rafaella Lopes Carvalho, Willyanna Ravanielly Oliveira de Jardim, Even Kaline Varella |
author_role |
author |
author2 |
Oliveira, Letícia Macêdo de Rodrigues, Yasmim Campos Santos, Luciane de Jesus Mendes Ferreira, Rafaella Lopes Carvalho, Willyanna Ravanielly Oliveira de Jardim, Even Kaline Varella |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Araújo, Cristiene Neta de Sá Oliveira, Letícia Macêdo de Rodrigues, Yasmim Campos Santos, Luciane de Jesus Mendes Ferreira, Rafaella Lopes Carvalho, Willyanna Ravanielly Oliveira de Jardim, Even Kaline Varella |
dc.subject.por.fl_str_mv |
Inibidores do transportador 2 de sódio-glicose Falência renal crônica Diabetes mellitus tipo 2. Inhibidores del transportador de sodio-glucosa 2 insuficiencia renal crónica Diabetes mellitus tipo 2. Sodium-glucose transporter 2 inhibitors Chronic kidney failure Type 2 diabetes mellitus. |
topic |
Inibidores do transportador 2 de sódio-glicose Falência renal crônica Diabetes mellitus tipo 2. Inhibidores del transportador de sodio-glucosa 2 insuficiencia renal crónica Diabetes mellitus tipo 2. Sodium-glucose transporter 2 inhibitors Chronic kidney failure Type 2 diabetes mellitus. |
description |
Chronic kidney disease (CKD) is characterized by progressive kidney damage with a drop in glomerular filtration rate for a period longer than three months. Among the main causes of CKD in the Brazilian population are type 2 diabetes mellitus (DM2) and systemic arterial hypertension (SAH). Drug therapy with Sodium-glucose cotransporter type 2 inhibitors (iSGLT-2) allows control of the loss of renal function and decreases the need for patients to need renal replacement therapy such as hem dialysis. Objective: To understand the effects of iSGLT-2 in reducing renal outcome, in order to know its benefits and adverse events. Methodology: This is an integrative literature review from the january 2017 to january the 2022, in the electronic databases SCIELO, PUBMED and LILACS, including work in Portuguese and English. The flow diagram was used as a tool for organizing and analyzing the articles. The works of interest were analyzed and then the results with their respective bibliographic data were organized in a frame. Results: Twelve randomized clinical trials were analyzed, of which 5 (42%) studies on canagliflozin, 4 (33%) studies on dapagliflozin, 2 (17%) on empagliflozin and only 1 (8%) study on ertugliflozin. Conclusion: SGLT-2 inhibitors are a new class of drugs that have been shown in several studies to reduce unfavorable renal outcomes, with few side effects, proving to be an important therapeutic tool in the treatment of the population of patients with renal disease. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-03-20 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/40810 10.33448/rsd-v12i3.40810 |
url |
https://rsdjournal.org/index.php/rsd/article/view/40810 |
identifier_str_mv |
10.33448/rsd-v12i3.40810 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/40810/33295 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 12 No. 3; e29512340810 Research, Society and Development; Vol. 12 Núm. 3; e29512340810 Research, Society and Development; v. 12 n. 3; e29512340810 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052620634849280 |